Skip to main content
SpringerLink
Log in

Benzodiazepines: higher risk of AD in Canadian elderly?

  • Comment
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Each patient with AD (case) was matched on gender, age group (70-74, 75-79, 80-84 or ≥85 years), and duration of follow-up (6, 7, 8, 9 or 10 years).

References

  1. Billioti de Gage S, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 349: g5205 [10 pages], 09 Sep 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5205

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yaffe K, et al. Benzodiazepines and risk of Alzheimer’s disease. BMJ 349: g5312 [3 pages], 09 Sep 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5312

    Article  PubMed  Google Scholar 

  3. Kmietowicz Z. Benzodiazepines may be linked to Alzheimer’s disease, study finds. BMJ 349: g5555 [2 pages], 09 Sep 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5555

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benzodiazepines: higher risk of AD in Canadian elderly?. Reactions Weekly 1519, 11 (2014). https://doi.org/10.1007/s40278-014-3430-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-3430-9

Search

Navigation